Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Net Margin (2016 - 2025)

ImmunityBio (IBRX) has disclosed Net Margin for 12 consecutive years, with 161.83% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 62179.0% to 161.83% in Q4 2025 year-over-year; TTM through Dec 2025 was 310.25%, a 249508.0% increase, with the full-year FY2025 number at 310.25%, up 249508.0% from a year prior.
  • Net Margin was 161.83% for Q4 2025 at ImmunityBio, up from 209.83% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 161.83% in Q4 2025 to a low of 735700.0% in Q1 2022.
  • A 5-year average of 124845.13% and a median of 45142.08% in 2021 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: skyrocketed 198103274bps in 2021, then plummeted -67780000bps in 2022.
  • ImmunityBio's Net Margin stood at 23475.13% in 2021, then tumbled by -532bps to 148391.78% in 2022, then decreased by -13bps to 167923.74% in 2023, then soared by 100bps to 783.62% in 2024, then soared by 79bps to 161.83% in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Net Margin are 161.83% (Q4 2025), 209.83% (Q3 2025), and 350.33% (Q2 2025).